Researchers are excited about the medication , a novel dual compound showing promising outcomes in clinical trials for body management. It acts by targeting several pathways : GLP-1 and GIP, which , when activated , help control hunger and enhance energy expenditure . Early observations demonstrate considerable weight reduction and potential improv